Its not known whether Nurtec ODT (rimegepant) is safe to take while pregnant or breastfeeding. Certain factors, including the risks of not treating your condition during pregnancy, may determine ...

Happily for investors, Pfizer is generating enough cash flow to cover its dividend. In 2024, it paid $9.5 billion in ...

Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Vlad Coric, M.D. to the company’s Board of Directors, effective immediately. Vlad Coric is the Chairman and Chief Executive Officer ...

You may know 175-year-old pharmaceutical company Pfizer (NYSE: PFE) best for its COVID-19 vaccine, but investors have long ...

The Department of Justice (DoJ) claims that Biohaven – before being acquired by Pfizer – paid "improper remuneration" to some Nurtec ODT (rimegepant) prescribers in the form of speaker fees ...

Pfizer's top-selling product last year was Eliquis, which it co-markets with Bristol Myers Squibb. The blood thinner generated revenue for Pfizer of nearly $7.4 billion last year. It loses patent ...

Pfizer's growth is boosted by Nurtec ODT, acquired from Biohaven and Padcev from the Seagen acquisition. By 2030, Pfizer aims to add $25 billion to its top line. Pfizer has already boosted its ...

Although the company will lose patent exclusivity for several top drugs, it also has newer products on the market, such as cancer therapies Adcetris and Padcev along with migraine drug Nurtec ODT ...

Migraine is the third most common illness in the world, with about 14 percent of the global population experiencing migraine ...

We recently published a list of 8 Most Undervalued Healthcare Stocks to Buy According to Analysts. In this article, we are going to take a look at where Royalty Pharma Plc (NASDAQ:RPRX) stands against ...